Literature DB >> 33609792

Rheumatoid arthritis: Extra-articular manifestations and comorbidities.

Fabiana Assunta Figus1, Matteo Piga2, Irene Azzolin1, Rebecca McConnell3, Annamaria Iagnocco4.   

Abstract

Although synovitis is the pathological hallmark of rheumatoid arthritis (RA), many extra-articular manifestations (EMs) and comorbidities likely occur due to the complex, chronic, inflammatory, and autoimmune features of RA. Cardiovascular (CV) disease is the most common cause of death in patients with RA. Compared to the general population, patients with RA have twice the risk of myocardial infarction and up to 50% increased CV mortality risk. Severe and prolonged disease activity, genetics, and inflammation (e.g. CRP, ACPA, cytokines, matrix-degrading enzymes) play important roles in CV disease and atheroscleroticdamage. The second major cause of death in patients with RA is respiratory disease, which occurs in 30-40% of patients. RA may affect the lung interstitium, airways, and pleurae, while pulmonary vascular involvement is less frequent. Central and peripheral nervous system involvement is usually due to small vessel vasculitis, joint damage, or drug toxicity. There is also evidence that microvascular cerebral damage caused by systemic inflammation is associated with the development of Alzheimer's disease and vascular dementia. Some observational studies have hinted how Disease Modified Anti-Rheumatic Drugs and biologics could reduce the incidence of dementia. Primary gastrointestinal and renal involvements are rare and often relate to drug therapy. To minimize morbidity and mortality, physicians must manage RA disease activity (treat-to-target) and monitor risk factors and concomitant conditions (e.g. smoking cessation; weight regulation; monitoring blood pressure, lipids, thyroid hormone, folic acid and homocysteine; screening for depression, anxiety, atlantoaxial instability, and atherosclerosis). This article aims to provide an overview of the most prevalent and important EMs and comorbidities associated with RA.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Comorbidity; Complications; Extra-articular manifestation; Rheumatoid arthritis

Mesh:

Substances:

Year:  2021        PMID: 33609792     DOI: 10.1016/j.autrev.2021.102776

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  20 in total

1.  The comparison of cardiovascular disease risk prediction scores and evaluation of subclinical atherosclerosis in rheumatoid arthritis: a cross-sectional study.

Authors:  Hafis Muhammed; Durga Prasanna Misra; Neeraj Jain; Sujata Ganguly; Sarit Sekhar Pattanaik; Mohit K Rai; Anamika Kumari Anuja; Namita Mohindra; Sudeep Kumar; Vikas Agarwal
Journal:  Clin Rheumatol       Date:  2022-08-25       Impact factor: 3.650

2.  Plasma IL-36α and IL-36γ as Potential Biomarkers in Interstitial Lung Disease Associated with Rheumatoid Arthritis: a Pilot Study in the Chinese Population.

Authors:  Weishuai Zheng; Xingxing Hu; Menglin Zou; Nie Hu; Weiwei Song; Rui Wang; Ying Liu; Qinhui Hou; Yuan Liu; Xiaoqi Chen; Zhenshun Cheng
Journal:  Inflammation       Date:  2022-08-31       Impact factor: 4.657

3.  Vascular Age, Metabolic Panel, Cardiovascular Risk and Inflammaging in Patients With Rheumatoid Arthritis Compared With Patients With Osteoarthritis.

Authors:  Gabriel-Santiago Rodríguez-Vargas; Pedro Santos-Moreno; Jaime-Andrés Rubio-Rubio; Paula-Katherine Bautista-Niño; Darío Echeverri; Luz-Dary Gutiérrez-Castañeda; Fabio Sierra-Matamoros; Stephania Navarrete; Anggie Aparicio; Luis Saenz; Adriana Rojas-Villarraga
Journal:  Front Cardiovasc Med       Date:  2022-07-05

Review 4.  A Review of Metabolomic Profiling in Rheumatoid Arthritis: Bringing New Insights in Disease Pathogenesis, Treatment and Comorbidities.

Authors:  Bárbara Jonson Bartikoski; Marianne Schrader De Oliveira; Rafaela Cavalheiro Do Espírito Santo; Leonardo Peterson Dos Santos; Natália Garcia Dos Santos; Ricardo Machado Xavier
Journal:  Metabolites       Date:  2022-04-27

5.  Association Between Metabolic Dysfunction-Associated Fatty Liver Disease and Cardiovascular Risk in Patients With Rheumatoid Arthritis: A Cross-Sectional Study of Chinese Cohort.

Authors:  Yao-Wei Zou; Qian-Hua Li; Jing-Wei Gao; Jie Pan; Jian-Da Ma; Le-Feng Chen; Jian-Zi Lin; Ying-Qian Mo; Xue-Pei Zhang; Pin-Ming Liu; Lie Dai
Journal:  Front Cardiovasc Med       Date:  2022-05-13

6.  Biological Anti-TNF-α Therapy and Markers of Oxidative and Carbonyl Stress in Patients with Rheumatoid Arthritis.

Authors:  Emőke Šteňová; Martina Bakošová; Lucia Lauková; Peter Celec; Barbora Vlková
Journal:  Oxid Med Cell Longev       Date:  2021-12-22       Impact factor: 6.543

Review 7.  Folate Receptor Beta for Macrophage Imaging in Rheumatoid Arthritis.

Authors:  Maarten M Steinz; Aiarpi Ezdoglian; Fatemeh Khodadust; Carla F M Molthoff; Madduri Srinivasarao; Philip S Low; Gerben J C Zwezerijnen; Maqsood Yaqub; Wissam Beaino; Albert D Windhorst; Sander W Tas; Gerrit Jansen; Conny J van der Laken
Journal:  Front Immunol       Date:  2022-02-02       Impact factor: 7.561

Review 8.  Neuroimmune Crosstalk in Rheumatoid Arthritis.

Authors:  Dashuang Gao; Xu Gao; Fan Yang; Qingwen Wang
Journal:  Int J Mol Sci       Date:  2022-07-24       Impact factor: 6.208

9.  How long does it take to translate research findings into routine healthcare practice?-the case of biological drugs for rheumatoid arthritis in Brazil.

Authors:  Evandro de Oliveira Lupatini; Ivan Ricardo Zimmermann; Jorge Otávio Maia Barreto; Everton Nunes da Silva
Journal:  Ann Transl Med       Date:  2022-07

10.  Association between Hematological Indicesand Disease Activity in Patients with Rheumatoid Arthritis Treated with Janus Kinase Inhibitors for 24 Weeks.

Authors:  Jung-Yoon Choe; Seong-Kyu Kim
Journal:  Medicina (Kaunas)       Date:  2022-03-15       Impact factor: 2.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.